Control Bionics Ltd
ASX:CBL
Intrinsic Value
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. [ Read More ]
The intrinsic value of one
CBL
stock under the Base Case scenario is
0.127
AUD.
Compared to the current market price of 0.043 AUD,
Control Bionics Ltd
is
Undervalued by 66%.
Control Bionics Ltd's market capitalization is 5.1m AUD.
CBL stock price is 0.043 AUD.
CBL stock price (0.043 AUD) is 66% less than its Intrinsic Value (0.127 AUD).
CBL. Open DCF Valuation
CBL stock price (0.043 AUD) is 66% less than its Relative Value (0.127 AUD). Open Relative Valuation
CBL has upside potential of 40% compared to the average analyst price target.
Open Wall St Estimates
CBL's Revenue has grown by an exceptional 23% over the past 12 months.
CBL's Revenue is forecast to grow at a rate of 34% per year over the next 3 years.
CBL has negative Operating Income for the last twelve months.
CBL has negative Net Income for the last twelve months.
CBL's ROE (Return on Equity) for the past 12 months is negative and is equal to -55%.
CBL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -69%.
CBL has positive Gross Profit for the last twelve months.
CBL has negative Free Cash Flow for the last twelve months.
CBL's short-term assets (4m AUD) exceed its short-term liabilties (1m AUD).
CBL's D/E (Debt to Equity) is very low and is equal to 0.01.
CBL has negative three-year average ROE (Return on Equity): -51%. The company is not efficient at transforming stockholders' equity into net income.
CBL has negative three-year average ROIC (Return on Invested Capital): -81%. The company is not efficient at using invested capital to generate operating income.
CBL's long-term assets (9m AUD) exceed its long-term liabilties (1m AUD).
CBL has negative Net Debt. This means that the company has more cash and short-term investments (1m AUD) than debt (47k AUD).
CBL's Altman Z-Score is very low and is equal to -2.18.
CBL earns more than enough operating income (-5m AUD) to safely cover interest payments on its debt (-19k AUD).
Valuation Backtest
Control Bionics Ltd
Run backtest to discover the historical profit from buying and selling
CBL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Control Bionics Ltd
Balance Sheet Decomposition
Control Bionics Ltd
| Current Assets | 3.8m |
| Cash & Short-Term Investments | 1.3m |
| Receivables | 1.9m |
| Other Current Assets | 596.5k |
| Non-Current Assets | 5.1m |
| PP&E | 966.1k |
| Intangibles | 4.1m |
| Current Liabilities | 1.2m |
| Accounts Payable | 970.1k |
| Accrued Liabilities | 149.9k |
| Other Current Liabilities | 32.2k |
| Non-Current Liabilities | 69.4k |
| Long-Term Debt | 46.5k |
| Other Non-Current Liabilities | 22.8k |
Earnings Waterfall
Control Bionics Ltd
|
Revenue
|
6.4m
AUD
|
|
Cost of Revenue
|
-1.5m
AUD
|
|
Gross Profit
|
4.9m
AUD
|
|
Operating Expenses
|
-9.7m
AUD
|
|
Operating Income
|
-4.8m
AUD
|
|
Other Expenses
|
-15k
AUD
|
|
Net Income
|
-4.8m
AUD
|
Free Cash Flow Analysis
Control Bionics Ltd
CBL Profitability Score
Profitability Due Diligence
Control Bionics Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Control Bionics Ltd's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
CBL Solvency Score
Solvency Due Diligence
Control Bionics Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Score
Control Bionics Ltd's solvency score is 78/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CBL Price Targets Summary
Control Bionics Ltd
According to Wall Street analysts, the average 1-year price target for
CBL
is 0.06 AUD
.
Shareholder Return
CBL Price
Control Bionics Ltd
| Average Annual Return | -45.79% |
| Standard Deviation of Annual Returns | 20.23% |
| Max Drawdown | -97% |
| Market Capitalization | 5.1m AUD |
| Shares Outstanding | 117 924 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Control Bionics Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-07. The firm is principally engaged in development, commercialization and sale of assistive communications technology systems namely NeuroNode within the disability sector. The Group’s core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment and external control of other devices. Its NeuroNode Trilogy system combines its NeuroNode with eye-gaze technology to create a communication system. Its NeuroNode3 combines the NeuroNode wearable device with operating systems and is suitable for users with severe impairment. Its geographical locations consist of Australia, which is engaged in sales of Trilogy units and components in Australia, and North America, which is engaged in manufacturing and sales of Trilogy units and components in North America.
Contact
IPO
Employees
Officers
The intrinsic value of one
CBL
stock under the Base Case scenario is
0.127
AUD.
Compared to the current market price of 0.043 AUD,
Control Bionics Ltd
is
Undervalued by 66%.
You don't have any saved screeners yet
